webinar
Live Imaging of the Extracellular Matrix With a Glycan-Binding Fluorophore
June 9th, 2026 10:00 AM EDT
Register
Shopping Cart 0
Tel:
Email:
  1. Home
  2. Products
  3. Drug Discovery
  4. Inhibitor
  5. Cardiovascular and blood system
  6. HMG-CoA Reductase (HMGCR)
  7. Pitavastatin
Pitavastatin
Pitavastatin Chemical Structure

Pitavastatin

Catalog NO.: 147511-69-1 CAS NO.: 147511-69-1 Brand: BOC Sciences

Category
Inhibitor
Tag/Targets
HMG-CoA Reductase (HMGCR)
Molecular Formula
C25H24FNO4
Molecular Weight
421.46

Price Inquiry

WARNING: Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

cGMP Capacity

  • kg to MT scale
  • GMP batches production
  • Over 20 years of experience
  • HPAPI production with OEL < 1 μg/m³
  • Cleanroom Class 100 to Class 100,000
  • Special type of reactions in cGMP workshop
  • Cleaning level: Class A B C
  • cGMP synthesis workshop
Read More

Product Description

Pitavastatin, also called as itavastatin, is a potent HMG-CoA reductase inhibitor. And studies showed that pitavastatin inhibited the activity of Rho-kinase depending on the inactivation of Rho by inhibiting the mevalonate pathway. IC50: HepG2=5.8 nM

Quantity
Grams-Kilos
Boiling Point
692.0±55.0 °C (Predicted)
Density
1.352±0.06 g/cm3 (Predicted)
InChI Key
VGYFMXBACGZSIL-MCBHFWOFSA-N
InChI
InChI=1S/C25H24FNO4/c26-17-9-7-15(8-10-17)24-20-3-1-2-4-22(20)27-25(16-5-6-16)21(24)12-11-18(28)13-19(29)14-23(30)31/h1-4,7-12,16,18-19,28-29H,5-6,13-14H2,(H,30,31)/b12-11+/t18-,19-/m1/s1
SMILES
C1CC1C2=NC3=CC=CC=C3C(=C2C=CC(CC(CC(=O)O)O)O)C4=CC=C(C=C4)F
NCT NumberTitleCondition Or DiseasePhaseStart DateSponsorStatus
NCT00242944Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome (JAPAN-ACS)Coronary DiseasePhase 4November 2005Kyoto UniversityCompleted
NCT00249249Study to Compare the Efficacy of Pitavastatin With That of Atorvastatin in Lowering Cholesterol LevelsPrimary HypercholesterolemiaPhase 3October 2005Kowa Research EuropeCompleted
NCT00257686Study to Compare the Efficacy and Safety of Pitavastatin and Pravastatin in Elderly PatientsHypercholesterolemia or Combined DyslipidemiaPhase 3September 2005Kowa Research EuropeCompleted
NCT00309738Study to Compare the Efficacy and Safety of Pitavastatin and SimvastatinHypercholesterolemiaPhase 3September 2005Kowa Research EuropeCompleted
NCT00309751Study Comparing Pitavastatin and Atorvastatin in Patients With Type II Diabetes Mellitus and Combined DyslipidemiaType II Diabetes MellitusPhase 3December 2005Kowa Research EuropeCompleted
Write a review Ask a question
1.Clinical benefits of pitavastatin: focus on patients with diabetes or at risk of developing diabetes.
Barrios V1, Escobar C2. Future Cardiol. 2016 Apr 14. [Epub ahead of print]
Despite attaining LDL-cholesterol targets, many patients with diabetes remain at risk of developing cardiovascular events. In addition, treatment with statins has been associated with a slight but significant increased risk of development of diabetes, particularly with high-intensity statins. Pitavastatin is a moderate- to high-intensity statin that effectively reduces LDL-cholesterol levels. Pitavastatin provides a sustained increase of HDL-cholesterol levels that may exhibit a neutral or positive effect on glucose metabolism, may not increase the risk of new-onset diabetes, may exhibit positive effects on renal function and urinary albumin excretion and the risk of drug-drug interactions is low. Therefore, it seems that pitavastatin should preferentially be considered in the treatment of dyslipidemia in diabetic patients or at risk of developing diabetes.
2.Serum CETP status is independently associated with reduction rates in LDL-C in pitavastatin-treated diabetic patients and possible involvement of LXR in its association.
Shimada A1, Kimura H2, Oida K3, Kanehara H4, Bando Y4, Sakamoto S5, Wakasugi T6, Saga T7, Ito Y8, Kamiyama K9, Mikami D9, Iwano M9, Hirano T10, Yoshida H9,11. Lipids Health Dis. 2016 Mar 17;15(1):57. doi: 10.1186/s12944-016-0223-6.
BACKGROUND: Statins decrease cholesteryl ester transfer protein (CETP) levels, which have been positively associated with hepatic lipid content as well as serum low density lipoproteins-cholesterol (LDL-C) levels. However, the relationship between the CETP status and statin-induced reductions in LDL-C levels has not yet been elucidated in detail. We herein examined the influence of the CETP status on the lipid-reducing effects of pitavastatin in hypercholesterolemic patients with type 2 diabetes mellitus as well as the molecular mechanism underlying pitavastatin-induced modifications in CETP levels.
3.Pitavastatin versus Pravastatin in Reduction of Remnant Lipoprotein Cholesterol in Patients with Dyslipidemias.
Roever L1. Clin Ther. 2016 Mar 31. pii: S0149-2918(16)30156-4. doi: 10.1016/j.clinthera.2016.03.019. [Epub ahead of print]
Remnant lipoproteins cholesterol are products of partially catabolized chylomicrons and very-low-density lipoprotein, from which some triglycerides have been removed. These particles are smaller and are believed to be strongly atherogenic. Elevated Remnant lipoproteins cholesterol levels were reported to be associated with endothelial dysfunction and atherosclerotic disease.
Preparing Stock Solutions
ConcentrationVolumeMass1 mg5 mg10 mg
1 mM2.3727 mL11.8635 mL23.727 mL
5 mM0.4745 mL2.3727 mL4.7454 mL
10 mM0.2373 mL1.1864 mL2.3727 mL
About Us

BOC Sciences is a trusted global supplier of research chemicals, biochemicals, and pharmaceutical ingredients, serving the life sciences, biotech, and pharmaceutical industries. Headquartered in New York, we offer a comprehensive product portfolio that includes inhibitors, building blocks, carbohydrates, nucleosides, nucleotides, GMP products, impurities and metabolites, APIs, natural compounds, ADC-related chemicals, and stem cell molecules.

We specialize in the synthesis, biosynthesis, purification, and characterization of small molecules. With years of industry experience, our scientific and technical teams support projects ranging from early discovery to process development and regulatory submission.

BOC Sciences operates GMP-compliant and ISO-certified production facilities, ensuring consistent quality and regulatory alignment. Our products and services are trusted by clients in over 60+ countries, including top pharmaceutical companies, academic institutions, and research organizations.

We are committed to providing high-quality chemicals, responsive technical support, and flexible custom solutions to accelerate innovation in drug discovery and development.

Our Clients

Online Inquiry

Basic Information
How did you hear about BOC Sciences?
Verification code